8-K: Spruce Biosciences Issues Special Preferred Stock to Executive Chair to Facilitate Future Reverse Stock Split Vote

Spruce Biosciences, Inc. has issued a single share of Series A Preferred Stock to its Executive Chair, Michael Grey, granting significant voting power solely for a potential reverse stock split, with votes mirroring common shareholder sentiment.

Summary

• Spruce Biosciences, Inc. (SPRB) entered into a Purchase Agreement on May 28, 2025, to sell one share of newly designated Series A Preferred Stock to Michael Grey, the Executive Chair of the Board, for $100.00.
• The Series A Preferred Stock carries 22,000,000 votes, but its voting rights are exclusively limited to any 'Reverse Stock Split Proposal' submitted to stockholders.
• Crucially, the holder of the Series A Preferred Stock (Michael Grey) is obligated to cast these votes in the same proportion as the votes cast by common stockholders on a Reverse Stock Split Proposal, excluding abstentions and broker non-votes.
• The Series A Preferred Stock is not convertible into other shares and has a liquidation preference of $100.00.
• Transfer of the Series A Preferred Stock is restricted prior to stockholder approval of a Reverse Stock Split Proposal without Board consent.
• The share will be automatically redeemed for $100.00 upon stockholder approval of a Reverse Stock Split Proposal or if ordered by the Board.
• The Company plans to hold its 2025 Annual Meeting of Stockholders on July 22, 2025, with a record date of May 30, 2025.
• Revised deadlines for stockholder proposals for the 2025 Annual Meeting are June 5, 2025, for Rule 14a-8 proposals and other business, and June 8, 2025, for director nominee notices under universal proxy rules.

Sentiment

Score: 6

Explanation: The document addresses a necessary corporate action (potential reverse stock split) to improve stock market standing, which is a positive step. However, the underlying reason (trading on OTC Pink Marketplace) indicates challenges. The mechanism for the preferred stock's voting rights is designed to align with common shareholders, which is a neutral to slightly positive governance aspect.

Positives

• The issuance of Series A Preferred Stock provides a mechanism to facilitate a potential reverse stock split, which could be crucial for meeting listing requirements of a major exchange, especially given the company's recent move to the OTC Pink Marketplace.
• The voting structure for the Series A Preferred Stock ensures that its significant voting power on a reverse stock split proposal will align with the actual votes cast by common stockholders, preventing a single holder from unilaterally dictating the outcome against common shareholder will.
• The defined redemption terms for the Series A Preferred Stock ensure its temporary nature and clear exit strategy once its specific purpose is served.

Negatives

• The company's common stock began trading exclusively on the OTC Pink Marketplace on April 29, 2025, which is generally considered a less liquid and prestigious market compared to major exchanges.
• While the voting mechanism is designed to mirror common stock votes, the concentration of 22,000,000 votes in a single share held by the Executive Chair introduces a unique and potentially complex governance structure, even if its application is limited.
• The need for a reverse stock split often indicates a low share price, which can be a negative signal regarding investor confidence or company performance.

Risks

• Failure to obtain stockholder approval for a Reverse Stock Split Proposal could prevent the company from potentially regaining compliance with major exchange listing standards, leading to continued trading on the OTC Pink Marketplace.
• The company's stock trading on the OTC Pink Marketplace may result in reduced liquidity, lower investor interest, and difficulty in raising capital.
• The specific and limited voting rights of the Series A Preferred Stock, while designed to align with common shareholder votes, could still be perceived as a complex or unusual governance arrangement.

Future Outlook

The company's future outlook is focused on holding its 2025 Annual Meeting, where a Reverse Stock Split Proposal is expected to be presented. The newly issued Series A Preferred Stock is designed to facilitate the voting process for this proposal, aiming to potentially address issues related to the company's stock trading on the OTC Pink Marketplace.

Management Comments

• Samir Gharib, President and Chief Financial Officer, signed the 8-K report on behalf of Spruce Biosciences, Inc.

Industry Context

This filing reflects a common strategy employed by biotechnology or pharmaceutical companies, particularly those with low share prices, to prepare for a reverse stock split. Such actions are often taken to meet minimum bid price requirements for continued listing on major stock exchanges, or to improve stock attractiveness to institutional investors. The move to the OTC Pink Marketplace suggests the company may have already faced or is anticipating delisting from a higher-tier exchange.

Comparison to Industry Standards

• The use of a special class of preferred stock with super-voting rights tied to a specific corporate action (like a reverse stock split) is a known, albeit less common, corporate governance mechanism. It's typically employed when a company needs to ensure a specific outcome for a critical vote, while attempting to maintain alignment with common shareholder sentiment.
• Many companies facing low share prices opt for reverse stock splits to increase their per-share price and meet exchange listing requirements. For example, other small-cap biotech firms that have fallen below NASDAQ's minimum bid price often announce reverse splits to regain compliance.
• The structure where the preferred stock's vote mirrors common stock votes is a specific design choice to mitigate concerns about disproportionate control, differentiating it from preferred shares that grant outright control to a single holder.

Corporate Governance

Related Party Transactions

• Spruce Biosciences, Inc. sold one share of Series A Preferred Stock to Michael Grey, the Executive Chair of the Company's Board of Directors, for $100.00.

Stakeholder Impact

• Shareholders: The potential reverse stock split will reduce the number of outstanding shares and increase the per-share price, which could impact liquidity and market perception. The new voting structure for the reverse split ensures their collective vote is reflected.
• Management/Board: The Board, particularly the Executive Chair, gains a mechanism to facilitate a critical corporate action (reverse stock split) that may be necessary for the company's market standing.

Next Steps

• The Company will hold its 2025 Annual Meeting of Stockholders on July 22, 2025.
• Stockholders may submit proposals for the 2025 Annual Meeting by June 5, 2025.
• Stockholders intending to submit director nominations must provide notice by June 8, 2025.
• A Reverse Stock Split Proposal is expected to be presented to stockholders at the 2025 Annual Meeting.

Key Dates

Recommendation

Keywords

Spruce Biosciences, Series A Preferred Stock, Reverse Stock Split, Corporate Governance, SEC Filing, 8-K, OTC Pink Marketplace, Stockholder Meeting, Voting Rights, Equity Issuance